A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors

NCT00994071 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

NIH

Sponsor class

Conditions

Medulloblastoma
Pontine Glioma
Ependymoma
Astrocytoma
PNET

Interventions

DRUG: Temozolomide
DRUG: ABT-888

Sponsor

National Cancer Institute (NCI)